NCT07545044 2026-04-22
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
Clinical Trials
18 trialsNCT07527806 2026-04-17
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
Peking University Cancer Hospital & Institute
Phase 2 Not yet recruiting
NCT07518173 2026-04-08
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT07432178 2026-04-02
CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）
Fudan University
Phase 3 Not yet recruiting
NCT07423611 2026-02-20
RACE
Fudan University
Phase 2 Not yet recruiting
NCT07402473 2026-02-11
EUREKA Study:Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Not yet recruiting
NCT07246317 2025-11-28
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Not yet recruiting
NCT07220135 2025-10-23
NeoTHERa
University of Kansas Medical Center
Phase 2 Not yet recruiting
NCT07136974 2025-08-22
Efficacy of TQB2102 Versus TCbHP in Neoadjuvant Therapy for HER2-positive Early Breast Cancer.
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT07116824 2025-08-12
HB1801 Combined Treatment of HER2-positive Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT07093931 2025-07-30
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
Shandong Cancer Hospital and Institute
Phase 4 Not yet recruiting
NCT07083505 2025-07-24
A Study Comparing the Efficacy and Safety of HB1801 With Taxotere® in Advanced Breast Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 2 Not yet recruiting
NCT06996093 2025-05-30
Chemotherapy Omission in HR-positive/HER2-negative Breast Cancer With Lymph Node Negative Disease Receiving Adjuvant Endocrine Therapy and CDK4/6 Inhibitor
Fudan University
Phase 3 Not yet recruiting
NCT06795503 2025-01-28
Non-Inferiority Study on MRNA-lncRNA Model in Low-Risk Triple-Negative Breast Cancer Patients
Fudan University
Phase 3 Not yet recruiting
NCT06684054 2024-11-12
STFREiYTNBC
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Not yet recruiting
NCT06470633 2024-06-24
To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT05287308 2022-03-31
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study
ChineseAMS
Phase NA Not yet recruiting
NCT05131893 2021-11-23
Neoadjuvant Treatment of Breast Cancer
National Institute of Oncology, Hungary
Not yet recruiting